View Document Preview and Link
Open Document File Size: 399,46 KB Share Result on Facebook
Company ICD Group / Boston Scientific / Guidant / CRT-D Group / BNP Labs / / Country United States / / Currency pence / / Event FDA Phase / / Facility University of Rochester / Hall WJ / / IndustryTerm clinical protocol / treatment of heart failure / therapy for heart failure / data management / center communications / randomized treatment / overall study management / / MedicalCondition severe heart failure / NYHA Class I-II heart failure / Mild heart failure / congestive heart failure / ventricular tachycardia / ventricular dysfunction / cardiomyopathy / sudden cardiac death / left ventricular dysfunction / heart block / Enzyme-positive myocardial infarction / non-ischemic heart disease / symptomatic heart failure / degree heart block / potential heart failure / Ventricular tachyarrhythmia therapy / Chronic / ischemic heart disease / myocardial infarction / prior myocardial infarction / acute viral myocarditis / advanced heart failure / heart failure / non-ischemic cardiomyopathy / dilated cardiomyopathy / optimal heart failure / ventricular fibrillation / atrial fibrillation / Asymptomatic heart failure / coronary disease / ventricular tachyarrhythmia / alcohol-induced heart disease / ischemic cardiomyopathy / / MedicalTreatment clinical protocol / Cardiac Resynchronization Therapy / surgeries / angioplasty / bypass / drug therapy / surgery / / Organization Heart Failure Event Committee / Independent Data Safety Monitoring Board / Food and Drug Administration / CRT Executive Committee / Center for Devices and Radiological Health / New York Heart Association / Mortality Endpoint Review Committee / FDA / University of Rochester / Division of Cardiovascular Devices / / Person Criteria Patients / / Position investigator / Executive / physician / / Product S165 / S008 / / ProvinceOrState Louisiana / / Technology clinical protocol / 29 7.7 Protocol / / SocialTag